New cocktail shows promise for tough head and neck cancer
NCT ID NCT05673577
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested a combination of three drugs—camrelizumab (an immunotherapy), cetuximab (a targeted therapy), and chemotherapy—as a first treatment for people with head and neck cancer that has come back or spread. The study enrolled 41 participants and measured how many had their tumors shrink or disappear. The goal is to find a more effective first-line option for this advanced cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab, cetuximab, albumin paclitaxel, cisplatin
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for patients with advanced head and neck cancer, potentially improving response rates and delaying disease progression.
- What could go wrong
- This is a small, single-center phase 2 trial with only 41 participants, so results may not apply broadly. The combination also carries risks of side effects from chemotherapy and immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- New antibody drug aims to unleash immune system on Hard-to-Treat cancers
- Could fewer radiation sessions after surgery improve quality of life for head and neck cancer patients?
- New drug combo offers hope for tough head and neck cancers
- Could a yeast vaccine stop Cancer's return?